The following table presents selected financial information with respect to the Company’s single operating segment for the quarters ended March 31, 2025, and 2024:


	Three Months Ended
(in thousands)	2025			2024
Product revenue, net	$	88,183		$	45,250
Cost of goods sold	5,028			2,419

Gross margin	94		%	95		%
B-VEC	1,973			2,129
KB105	7			15
KB301	38			176
KB304	242			131
KB407	349			783
KB408	298			245
KB707	2,738			1,419
KB801	454			51
KB803	486			—
Other dermatology programs	27			—


Other aesthetics programs	—			3
Other ophthalmology programs	27			49
Other research programs	393			251
Other development programs	226			232
Other research and development costs (1)	6,997			5,473
Total research and development	14,255			10,957
Selling, general and administrative	32,723			26,058
Litigation settlement	—			12,500
Income (loss) from operations	$	36,177		$	(6,684)

Other income

Interest and other income, net	7,420			7,616
Income before income taxes	$	43,597		$	932
Income tax expense	(7,864)			—
Net income	$	35,733		$	932

(1)Includes stock-based compensation, other manufacturing expenses related to our product candidates and other unallocated expenses which largely relates to depreciation and other facilities and equipment related costs